ArticleClinical and experimental immunology2009
Dexamethasone suppresses interleukin-22 associated with bacterial infection in vitro and in vivo.
Article in Clinical and experimental immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Assessment of Serum Interleukins 18 and 22 in Predicting Neonatal Sepsis and Mortality: A Case-Control Study.Clinical medicine insights. Pediatrics · 2026Article
- Dog allergen-induced asthma in mice: a relevant model of T2Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Steroid-Refractory Gut Graft-Versus-Host Disease: What We Have Learned From Basic Immunology and Experimental Mouse Model.Frontiers in immunology · 2022Review
- COVID-19: potential therapeutics for pediatric patients.Pharmacological reports : PR · 2021Review
- T cell cytokines in the diagnostic of early-onset sepsis.Pediatric research · 2021Article
- Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications.Life sciences · 2021Review
- Interleukin-22 and connective tissue diseases: emerging role in pathogenesis and therapy.Cell & bioscience · 2021Review
- Long-Term Accurate Continuous Glucose Biosensors via Extended Nitric Oxide Release.ACS sensors · 2019Article
- Increased granulysin in the peripheral blood and tissues of patients with oral lichen planus.International journal of clinical and experimental pathology · 2019Article
- IL-22/IL-22R1 axis is involved in myocardial injury of a mouse cecal ligation and puncture model.American journal of translational research · 2019Article
- Hypothermia Promotes Interleukin-22 Expression and Fine-Tunes Its Biological Activity.Frontiers in immunology · 2017Article
- A gradient of glucocorticoid sensitivity among helper T cell cytokines.Cytokine & growth factor reviews · 2016Review
- Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling.British journal of cancer · 2014Article
- In vivo analytical performance of nitric oxide-releasing glucose biosensors.Analytical chemistry · 2014Article
- Immunoregulation therapy changes the frequency of interleukin (IL)-22+ CD4+ T cells in systemic lupus erythematosus patients.Clinical and experimental immunology · 2014Article
- Biocompatible materials for continuous glucose monitoring devices.Chemical reviews · 2013Review
- Emerging role of interleukin-22 in autoimmune diseases.Cytokine & growth factor reviews · 2013Review
- Th17 cells: critical mediators of host responses to burn injury and sepsis.Journal of leukocyte biology · 2012Review
- Expressions of IL-22 in circulating CD4+/CD8+ T cells and their correlation with disease activity in SLE patients.Clinical and experimental medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin (IL)-22 production triggered by innate immune mechanisms has been identified as key to efficient intestinal anti-bacterial host defence and preservation of homeostasis. We hypothesized that glucocorticoid therapy may impair IL-22 expression, which should promote intestinal epithelial damage with the potential of subsequent bacterial translocation. High-dose corticosteroid therapy in Crohn's disease has been associated with an increased rate of abscess formation and ultimately with a higher risk of developing postoperative infectious complications, including abdominal sepsis. Thus, we sought to investigate effects of the prototypic glucocorticoid dexamethasone on IL-22 production in the context of bacterial infection. Enhanced IL-22 plasma levels were detectable in rat sepsis. Moreover, heat-inactivated Staphylococcus epidermidis, used as a prototypic activator of innate immunity, induced robust production of IL-22 by human peripheral blood mononuclear cells (PBMC). Here, we report for the first time that dexamethasone mediates remarkable suppression of IL-22 as detected in S. epidermidis-activated PBMC and rat sepsis, respectively. The data presented herein suggest that insufficient IL-22 function may contribute to impaired intestinal host defence in the context of corticosteroid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.